*Read Disclaimer Sponsored Content | Unsubscribe
Hello!
Following our alert this morning, NNVC opened at 1.16 and so far, rallied to a high of 1.21.
NNVC has been building a solid base for the past two months around current levels.
We have profiled this opportunity previously after which it rallied upwards of +35%, +53%, +44%.
For instance, in December, NNVC rallied +36% from current levels with a similar chart setup.
NNVC has a 20 and 50 day moving average of 1.18 and 1.27.
A breakout and close above these levels could present increased upside potential.
NNVC has a 200 day moving average of 1.41, +21% from today's open.
Above that, November's high of 2.23 is +92% from today's open.
As the company explained in their most recent press release from January:
NanoViricides' Current Antiviral Drugs Pipeline: NV-387, A Revolutionary Broad-Spectrum Antiviral with Multiple Indications
"The Phase II clinical stage revolutionary broad antiviral spectrum of NV-387 is reminiscent of the dawn of antibiotics to combat bacterial infections. Over 90% of human pathogenic viruses use heparan sulfate features, which NV-387 copies and presents to fool the virus."
"NV-387 is designed to attack the virus particle and destroy it by fooling the virus to enter the NV-387 nanomicelle using the same features that the virus uses to infect cells."
"Viruses cannot escape NV-387 despite all the changes in the field because the virus still needs to bind to heparan-sulfate like features in order to cause productive pathogenic infection. NV-387 presents copious amounts of these binding sites to the virus, thereby engulfing the virus particle. Viruses are unlikely to escape NV-387 because no matter how much a virus evolves, it continues to utilize and require binding to sulfated proteoglycans - the very characteristic that NV-387 emulates."
"This solves the long-standing problem of antiviral medicines, that viruses escape them. Vaccines, antibodies and small chemical drugs are readily escaped by viruses as the viruses evolve in the field. This has been repeatedly observed during the recent COVID-19 pandemic, as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS."
NV-387 for Influenza and Bird Flu
"NV-387 was found to be substantially superior to Tamiflu as well as Xofluza against Influenza virus A/H3N2 in animal model studies of Influenza A/H3N2 lethal lung infection [2]."
"Further, should Bird Flu H5N1 turn into a human outbreak, variants resistance to Tamiflu and Xofluza can be expected to generate rapidly [3]. NV-387 would be the ideal drug to combat the resulting outbreak, epidemic or pandemic. The causative influenza virus would not be able to escape NV-387 [4]."
NV-387 for All Respiratory Viral Infections
"A Phase II clinical trial for the evaluation of NV-387 as a first line therapy of any respiratory viral infection (NV-387 for the treatment of Viral Acute or Severe Acute respiratory Infections, Viral ARI/SARI) is being planned. Success in this clinical trial would enable NV-387 to become the first ever antiviral drug that can be prescribed by a physician based on symptoms, as an emperic therapy for respiratory viral infections, without having to test for which virus is causing the disease."
"NV-387 was found to be highly effective against the "tripledemic" respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. NV-387 was found to be substantially superior to existing drugs, and even resulted in complete cure in the RSV animal study. These studies prompted evaluation of NV-387 as a first line therapy of respiratory viral infections."
"There is no treatment approved for RSV, an important disease for infants and children in early life, as well as for geriatric subjects."
In addition, yesterday, the company announced:
NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference
"SHELTON, CT / ACCESS Newswire / January 20, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will participate in the DealFlow Discovery Conference, taking place January 28th and 29th, 2026."
"Anil R. Diwan, PhD, President and Executive Chairman of the Company will deliver a company presentation on Thursday, January 29th at 11:00 am ET, and will be available for one-on-one investor meetings throughout the event."
"Event Details:
- Conference: 3rd Annual DealFlow Discovery Conference
- Venue: The Borgata Hotel, Casino & Spa
- Location: Atlantic City, NJ"
- Date: January 28th-29th, 2026
Here are a couple of the things to keep in mind for upside potential.
Look for NNVC to make higher lows and higher highs. That is often the first sign of a more sustainable uptrend.
A strong close near the highs could help confirm a potential new leg higher.
A rally and close above the 20- and 50-day moving averages could result in increased upside.
In addition, NNVC has a RSI of 48 – showing upside potential.
We are continuing to monitor NNVC for a sustainable breakout higher.
Sources: PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, PR9, Website, Chart
Happy Trading!
UltimateStockAlerts Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
